[ Back to EurekAlert! ]

PUBLIC RELEASE DATE:
22-Oct-2012

[ | E-mail ] Share Share

Contact: Jennifer Stawarz
jstawarz@chestnet.org
847-498-8306
American College of Chest Physicians
@accpchest

Statins may help prolong survival in NSCLC resection

Patients who have undergone resection for non-small cell lung cancer (NSCLC) may improve their overall survival and reduce the risk of recurrence by taking statins.

Researchers from Northwestern University Feinberg School of Medicine, Chicago, and Penn State Hershey Cancer Institute followed 803 patients who underwent resection for NSCLC, of which 315 were using statins. Results showed that statin use was associated with a significantly lower local recurrence rate and significantly higher overall survival compared with non-statin users.

Researchers conclude that prospective studies are needed to assess the role of statin therapy as an adjunct to current multimodality regimens.

This study was presented during CHEST 2012, the annual meeting of the American College of Chest Physicians, held October 20 - 25, in Atlanta, Georgia.

###



[ Back to EurekAlert! ] [ | E-mail Share Share ]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.